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ABSTRACT
Objectives To investigate how the genetic
susceptibility gene DIO2 confers risk to osteoarthritis
(OA) onset in humans and to explore whether
counteracting the deleterious effect could contribute to
novel therapeutic approaches.
Methods Epigenetically regulated expression of DIO2
was explored by assessing methylation of positional
CpG-dinucleotides and the respective DIO2 expression in
OA-affected and macroscopically preserved articular
cartilage from end-stage OA patients. In a human in
vitro chondrogenesis model, we measured the effects
when thyroid signalling during culturing was either
enhanced (excess T3 or lentiviral induced DIO2
overexpression) or decreased (iopanoic acid).
Results OA-related changes in methylation at a specific
CpG dinucleotide upstream of DIO2 caused significant
upregulation of its expression (β=4.96; p=0.0016). This
effect was enhanced and appeared driven specifically by
DIO2 rs225014 risk allele carriers (β=5.58, p=0.0006).
During in vitro chondrogenesis, DIO2 overexpression
resulted in a significant reduced capacity of chondrocytes
to deposit extracellular matrix (ECM) components,
concurrent with significant induction of ECM degrading
enzymes (ADAMTS5, MMP13) and markers of
mineralisation (ALPL, COL1A1). Given their concurrent
and significant upregulation of expression, this process is
likely mediated via HIF-2α/RUNX2 signalling. In contrast,
we showed that inhibiting deiodinases during in vitro
chondrogenesis contributed to prolonged cartilage
homeostasis as reflected by significant increased
deposition of ECM components and attenuated
upregulation of matrix degrading enzymes.
Conclusions Our findings show how genetic variation
at DIO2 could confer risk to OA and raised the
possibility that counteracting thyroid signalling may be a
novel therapeutic approach.
INTRODUCTION
Osteoarthritis (OA) is a prevalent, complex, disab-
ling disease of articular joints, characterised by deg-
radation of articular cartilage and remodelling of
the subchondral bone. There is no effective therapy
to reverse or slow down the disease except for joint
replacement surgery at the end stage. As a result,
OA has a large detrimental impact on the quality of
life of the elderly and causes a major burden on
health and social care.1 To allow development of
new therapies, there is an ongoing need for insight
into the underlying mechanisms driving OA.
Genetic studies provided evidence that genes
orchestrating growth plate endochondral ossifica-
tion play a underlying role in common OA suscep-
tibility,2 hence functional follow-up approaches
require focus on both the early developmental and
late-acting effects of these OA genes. A notable
example is the deiodinase iodothyronine type 2
(D2) gene (DIO2) with the C-allele of the single
nucleotide polymorphism (SNP) rs225014 (fre-
quency ∼ 0.35) located in the coding region that
conferred consistent risk to OA.3 4 The gene
product of DIO2 is responsible for catalysing the
conversion of intracellular inactive thyroid
hormone (T4) to active thyroid hormone (T3). T3
subsequently signals terminal maturation of growth
plate chondrocytes leading to cell hypertrophy, car-
tilage matrix destruction mediated via upregulation
of hypoxia inducible factor-2α (HIF-2α) and
runt-related transcription factor-2 (RUNX2),5 6
mineralisation of the cartilage and eventually for-
mation of bone.7 There are striking parallels
between the chondrocyte signalling events that take
place in the growth plate and those of hypertrophic
chondrocytes in OA-affected articular cartilage.5
This has led to the hypothesis that with age and
environmental stresses the propensity of the highly
specialised, maturational arrested articular chondro-
cytes is affected by loss of epigenic control.
Progression of age and disease could result in
reactivation of genes involved in endochondral ossi-
fication, leading to loss and mineralisation of
articular cartilage, a process known to contribute to
OA.3 8–10 Functional genomic studies showed high
expression of DIO2 mRNA and D2 protein levels
in osteoarthritic as compared with healthy cartil-
age.5 11 12 Furthermore, DIO2 allelic imbalance
was assessed and showed that the OA risk allele ‘C’
was more abundantly present in articular joint
tissues than the wildtype allele ‘T’.11 In transgenic
rats, DIO2 overexpression conferred risk to articu-
lar cartilage destruction.13 The underlying mechan-
ism how the DIO2 SNP confers susceptibility to
OA in humans remains, however, to be
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determined,14 but most likely acts via aberrant upregulation of
its expression. The DIO2 locus in humans contains several puta-
tive CCCTC-binding factor (CTCF) binding sites, including one
that is overlapping with the rs225014 location.15 CTCF is con-
sidered to facilitate long-range chromatin interactions in order
to insulate gene expression, and distal transcriptional elements
on the genome are brought in close proximity to transcriptional
start sites (TSSs) of genes to inhibit expression.16
In the current study, we focus on regulatory mechanisms of
DIO2 expression in preserved and osteoarthritic human articu-
lar cartilage, thereby taking into account the DIO2 risk allele.
The direct effect of changes in DIO2 expression on chondrocyte
function and human cartilage extracellular matrix (ECM)
homeostasis is subsequently studied in human in vitro chondro-
genesis models, which should be considered a well-defined
system for studying changes in the ECM when chondrocytes dif-
ferentiate, become hypertrophic and start to exhibit cartilage-
debilitating expression patterns.
MATERIALS AND METHODS
The ongoing RAAK study is aimed at the biobanking of joint
materials (cartilage, bone and, where available, ligaments) and
mesenchymal stem cells and primary chondrocytes of patients in
the Leiden University Medical Center. In the current study, we
used paired preserved and OA-affected cartilage samples from
52 Caucasian end-stage OA patients undergoing joint replace-
ment surgery for primary OA (23 hips, 29 knees). For add-
itional details on the RAAK study, cell cultures, RNA and DNA
extraction, quantitative RT-PCR, ChIP and the data analysis, see
online supplemental methods.
Electrophoretic mobility shift assay
For electrophoretic mobility shift assays (EMSAs), synthetic oli-
gonucleotides containing the putative CTCF binding site were
50-end labelled by γ-32P-ATP and subsequently purified by gel fil-
tration on Sephadex G-25 Medium columns. For additional
details, see online supplemental methods.
Quantification of methylation
The methylated fraction of CpG dinucleotides was assessed with
MALDI-TOF mass spectrometry (Epityper, Sequenom), a com-
monly applied method to quantify CpG methylation.17–19 For
additional details, see online supplemental methods.
Lentiviral constructs and transduction
C-terminal FLAG-tagged cys-D2 (kindly provided by Prof.
Dr. Bianco20) was digested with EcoRI followed by Klenow
treatment and digestion with XbaI. Inserts were inserted into
the EcoRV-XbaI sites of the pLV-CMV-IRES-eGFP Lentiviral
backbone. For additional details, see online supplemental
methods.
In vitro chondrogenesis
3D pellets were formed using 2.5×105 human bone marrow-
derived mesenchymal stem cells (hBMSCs). Chondrogenesis was
initiated in serum-free chondrogenic differentiation medium.
From day 14 onwards, cell pellets were maintained either in the
standard chondrogenic differentiation medium or in the pres-
ence of T3 (10 nM) or IOP (10 μM). For additional details, see
online supplemental methods.
Relative pixel intensity
The relative pixel intensity was computed by loading the photos
into ImageJ (V.1.47).21–23 For additional details, see online sup-
plemental methods.
RESULTS
Epigenetic regulation of DIO2 expression by CpG
methylation in articular cartilage
Online available ChIP-seq data revealed multiple transcription
factors to bind the rs225014 locus of which CTCF was pre-
dicted to bind with the highest certainty (see online supplemen-
tary figure S1). To assess the regulatory properties of the CTCF
binding site overlapping rs225014 and to test whether the
rs225014 alleles directly affect the binding, we performed an
EMSA. The putative CTCF sequence overlapping rs225014
(DIO2-CTCF1) was found not functional nor, for that matter,
dependent of the rs225014 alleles (see online supplementary
figure S2, lanes 1–6).
As no further TFs were confidently predicted to bind the
rs225014 locus, we set out to elucidate putative regulatory mechan-
isms of DIO2, independent of the rs225014 base change. We, there-
fore, quantified expression of DIO2 and methylation of 23 CpG
dinucleotides across the DIO2 locus in macroscopically preserved
and OA-affected cartilage from joints of patients undergoing total
arthroplasty of the knee (N=29) or hip (N=23) (RAAK study; see
online supplementary table S1). We found borderline significant
upregulation of DIO2 expression (β=0.22, p=0.063, figure 1C) in
OA compared with preserved cartilage. Furthermore, we observed
several CpG dinucleotides to be differentially methylated between
preserved and OA-affected cartilage (see online supplementary table
S2). However, only for the CpG site 2031 base pairs upstream of the
DIO2 transcription start site (CpG-2031, figure 1A) we observed sig-
nificant differential methylation between OA and preserved cartilage
(β=0.028, p=0.0007, figure 1B) and a significant positive association
between methylation and DIO2 expression in all samples (β=4.959,
p=0.0016, figure 1D; see online supplementary table S2). To
confirm the regulatory properties of CpG-2031 onDIO2 expression,
we applied 5-aza-20-deoxycytidine (AZA), a demethylating agent, to
the culture medium in eight primary chondrocyte cultures derived
from preserved cartilage of total hip replacement patients. Addition
resulted in a decrease in methylation at CpG-2031 (p=0.003, figure
2A) corresponding to downregulation of DIO2 expression
(p=0.004, figure 2B). Having observed the association between
DIO2 expression and OA-associated methylation at CpG-2031, we
applied a multivariate model to assess the individual effects of
CpG-2031 methylation, joint site, sex, BMI, age and rs225014 alleles
on DIO2 expression in articular cartilage (see online supplementary
table S3). We could hereby ratify the association between increased
CpG-2031 methylation and DIO2 expression (β=4.008, p=0.019).
The most notable observation, however, was the significant independ-
ent association of rs225014 genotype on DIO2 expression
(β=0.557, p=0.0003), indicating additive effects of both genotype
and DNA methylation differences on DIO2 expression. This effect
appeared to be mainly driven by the risk allele. Upon stratification by
the rs225014 alleles, no significant differences were observed
between preserved and OA-affected cartilage among homozygous
carriers of the rs225014 wildtype allele T in methylation (β=0.018,
p=0.112, figure 1E) or expression (β=−0.017, p=0.929, figure 1F).
In carriers of the risk allele, however, an increase was observed in OA
cartilage compared with the preserved tissue, both in the difference
of CpG-2031 methylation (β=0.034, p=0.00002, figure 1H) and in
expression (β=0.35, p=0.012, figure 1I), concomitant with an
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Figure 1 A functional CpG dinucleotide (CpG-2031) significantly modulates DIO2 expression. (A) Schematic overview of the quantified CpG
dinucleotides in pooled preserved and paired osteoarthritis (OA)-affected samples across the DIO2 locus. (B) Methylation between preserved and
OA-affected samples for CpG dinucleotide located 2031 base pairs upstream (CpG-2031) of the DIO2 transcriptional start site (TSS) (GLMM, N=103,
β=0.028, p=0.001, Bonferroni adjusted; see also online supplementary table S2). (C) Real-time qRT-PCR data of DIO2 expression between preserved
and OA-affected cartilage (GLMM, N=87, β=0.22, p=0.063). (D) Association between methylation at CpG-2031 and DIO2 expression (GLMM, N=87,
β=4.959, p=0.002, Bonferroni adjusted for 23 CpG sites tested). (E) Methylation between preserved and OA-affected cartilage for CpG-2031 among
homozygous rs225014 wildtype allele carriers (GLMM, N=44, β=0.018, p=0.112). (F) Real-time qRT-PCR data of DIO2 expression between preserved
and OA-affected cartilage among homozygous rs225014 wildtype allele carriers (GLMM, N=36, β=−0.017, p=0.929). (G) Association between
methylation at CpG-2031 and DIO2 expression among homozygous rs225014 wildtype allele carriers (GLMM, N=36, β=3.863, p=0.050).
(H) Methylation between preserved and OA-affected cartilage for CpG-2031 among the heterozygous and homozygous carriers of the rs225014 risk
allele (GLMM, N=59, β=0.034, p=0.00002). (I) Real-time qRT-PCR data of DIO2 expression between preserved and OA-affected cartilage among
rs225014 risk allele carriers (GLMM, N=51, β=0.35, p=0.012). ( J) Association between methylation at CpG-2031 and DIO2 expression among
rs225014 risk allele carriers (GLMM, N=51, β=5.58, p=0.0006). *p<0.05, **p<0.01, ***p< 0.001. OA, osteoarthritic cartilage; P, preserved cartilage.
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increased association between methylation and expression (β=6.816,
p=0.00001, figure 1J). As expected, this association between expres-
sion and methylation was much smaller among homozygous wildtype
allele carriers (β=3.863, p=0.050, figure 1G).
DIO2 effects on in vitro chondrogenesis; DIO2
overexpression
To assess the direct effect of DIO2 upregulation upon cartilage
matrix homeostasis, we examined in vitro chondrogenesis of
hBMSCs in a pellet culture for five consecutive weeks and gen-
erated lentiviral-mediated overexpression of DIO2 (figure 3A
and online supplementary figure S3). As a result, we observed a
greatly reduced expression of genes encoding the main proteins
of articular cartilage ECM, COL2A1, ACAN and COL10A1 by
reverse transcriptase qPCR (p<0.0001; figure 3A). In parallel,
we observed profound and significant upregulated gene expres-
sion of the OA markers of hypertrophy and ECM breakdown
ADAMTS5, MMP13, RUNX2 and EPAS1 (encoding HIF-2α)
from 3 weeks onwards (p<0.05, figure 3A). Histology con-
firmed a reduced deposition of glycosaminoglycans (GAGs)
(figure 3B,C). Although we did not have data to apply proper
statistics to produce a significant number, pixel intensity mea-
surements of the pictures reproduced as in figure 3B,C showed
us a 35% difference after 35 days between control and DIO2
overexpressing pellets, concurrent with visual lower collagen
type II (COL2) and collagen type X (COL10) protein expression
by immunohistochemical staining at consecutive weeks com-
pared with controls (figure 3D–G).
DIO2 effects on in vitro chondrogenesis; thyroid hormone
signalling
To explore whether the effects of DIO2 overexpression are due to
enhanced thyroid signalling, we examined in vitro chondrogenesis
of hBMSCs from five different donors (see online supplementary
table S4) in pellet cultures for seven consecutive weeks (see online
supplementary figure S4) while adding active T3 to the chondro-
genic medium from two weeks onwards (figure 4A–F). Excess T3
resulted in a significant, progressive reduction in pellet sizes com-
pared with controls, at consecutive weeks of culturing (p<0.05,
figure 4G). Respective expression analyses showed a reduced
expression of the ECM genes ACAN and COL2A1 (figure 4J),
although the downregulation of COL2A1 appeared not statistically
significant. Assessing the chondrogenic potential by measuring the
ratio between COL2A1 and COL1A1 expression showed a
dramatic effect on the chondrogenic effect of the cell system upon
addition of T3 (figure 4I). Moreover, the OA markers of hyper-
trophy and ECM breakdown genes ADAMTS5, RUNX2 and
EPAS1 were consistently upregulated from 3 weeks of treatment
onwards across the donor cultures (p<0.05, figure 4J). The differ-
ences in mean expression of MMP13 between controls and
T3-treated cells across the donors at consecutive time points were
not significant. Immunohistochemical studies contributed to the
confirmation that excess T3 resulted in a reduced expression of
COL2 (figure 4C,D) and COL10 (figure 4E,F) and a pronounced
reduction of GAGs (figure 4A,B) as reflected by the reduced
Alcian blue staining at consecutive time points with an overall
mean decrease of 35% (p=0.0002) as measured by the quantita-
tive pixel intensities (figure 4H).
Pharmacological inhibition of D2
To investigate whether thyroid signalling blockade attenuates the
detrimental effect on cartilage matrix homeostasis, pellet cul-
tures were treated with the pharmacological deiodinase inhibitor
iopanoic acid (IOP) during in vitro chondrogenesis of hBMSCs
of the five donors. Quantification of surface areas indicated
increasing sizes at consecutive time points in the IOP-treated
pellets comparable to non-treated, control pellets (figure 5G).
Respective expression analyses showed a significantly increased
expression of the ECM genes ACAN, COL2A1 and COL10A1
after 3 weeks of treatment (p<0.01, figure 5J), whereas the OA
markers of hypertrophy and ECM breakdown genes ADAMTS5,
RUNX2 and EPAS1 were similar to control cultures (figure 5J).
Furthermore, we found no significant difference in chondro-
genic potential between control and IOP-treated pellets when
assessing the ratio between COL2A1 and COL1A1 expression
(figure 5I). Following these expression patterns, histological ana-
lysis of matrix components showed slightly higher levels of
COL2 and COL10 staining (figure 5C–F) and higher levels of
GAGs as reflected by a significant 4% increase in Alcian blue
staining at week 5 of treatment (p=0.018; figure 5A,B and H).
Of note is the denser cartilage matrix structure with less cellular
lacunae at week 5 of treatment in cells treated with IOP com-
pared with controls (figure 5A). By discriminating ‘cartilage’
from the ‘lacunae’ using the ImageJ data, we could show that
administration of IOP resulted in a 10.92% decrease of lacunae
(p=4.27×10−5) on day 35 of treatment.
Figure 2 Methylation regulates DIO2 expression in articular cartilage. Each pair of bars reflects a unique donor cell culture, derived from total hip
replacement patients. (A) Methylation at dinucleotide CpG-2031 without treatment (Control) and after treatment with 1.5 mM of the demethylating
agent 5-aza-2-deoxycytidine (AZA). (B) Real-time qRT-PCR data of DIO2 expression without treatment and after AZA treatment.
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DISCUSSION
In the current study, we provided insights into how genetic vari-
ation at the DIO2 locus confers risk to OA. As a result of
OA-related changes in articular cartilage, loss of epigenetic silen-
cing results in upregulation of DIO2 expression among DIO2
rs225014 risk allele carriers (figures 1 and 2). By applying an in
vitro chondrogenesis model with genetically modified hBMSC,
it was subsequently shown that genetic upregulation of DIO2
expression resulted in a marked reduction of the capacity of
chondrocytes to deposit ECM components, concurrent with
induction of OA-specific markers of cartilage matrix degener-
ation (ADAMTS5 and MMP13) and mineralisation (ALPL)
(figure 3). Given their concurrent upregulation, this process is
likely mediated via HIF-2α/RUNX2 signalling, a hallmark of the
OA disease process.6 24–26 Moreover, we show that the detri-
mental effects of DIO2 upregulation are a result of increased T3
synthesis as reflected by the identical results when adding T3 to
the culture medium (figure 4). Given that the effects observed
in both treatments are very similar and the fact that the specific
downstream effect of D2 action is the conversion of inactive T4
to active T3, we are confident that the reported effects in both
experiments are reflecting the same mechanism, although we
did not directly assess the levels of the trace element T3 in our
in vitro chondrogenesis model. Together our data are in line
with our previous observations that carriers of the DIO2 risk
allele are prone to improper endochondral ossification and
respective skeletal morphogenesis that could result in subtle mal-
formations of joints or articular cartilage ECM composition.27
In contrast, we showed that inhibiting deiodinases by addition
of IOP contributed to prolonged ‘healthy’ cartilage homeostasis
by virtue of attenuated upregulation of matrix degrading
enzymes, a constant COL2A1/COL1A1 ratio, denser cartilage
matrix structure with significant less cellular lacunae, which
indicates a reduced propensity of chondrocytes to enter the ter-
minal maturational process (figure 5). In view of these findings,
we advocate that attenuation of thyroid signalling by, for
example, inhibiting deiodinases could contribute to novel thera-
peutic options of OA or could improve outcomes of cartilage
tissue-engineering approaches. Nevertheless, given that T3 has
many and various biological functions, both in the circulation
and in a tissue-specific manner, local administration of a
thyroid-blocking agent is likely necessary and a challenging
aspect. Furthermore, the effect of, for example, IOP on other
joint tissues (eg, ligament and synovium) requires investigation.
It should be noted that IOP is a general inhibitor of deiodinases
and as such could have also inhibited D1 and D3 action. In this
respect, expression of DIO1, being important mainly in the cir-
culation, is likely absent in cartilage tissues. Furthermore, by
inhibiting D3, we prevented the conversion of active T3 to
inactive T4, thereby ruling out the effect of T3 depletion due to
inactive D2. Despite the beneficial effects of IOP, we observed
upregulation of COL10 similar to control cultures reflecting the
normal initiation of chondrocyte hypertrophy (figure 5J). Vice
versa, we showed that upon addition of T3 chondrocytes dir-
ectly enter the terminal maturational process towards bone, as
reflected by the upregulation of enzymatic breakdown
(ADAMTS5) and mineralisation (ALPL, COL1A1), this without
significant induction of COL10 deposition (figure 4E,F).
Together, these data indicate that chondrocyte hypertrophy in
our model was not necessarily detrimental to cartilage
Figure 3 Overexpressing DIO2 has a detrimental effect on cartilage extracellular matrix homeostasis. (A) qRT-PCR analysis of DIO2, COL2A1,
ACAN, COL10A1, RUNX2, EPAS1, MMP13, ADAMTS5 and ALPL at 21 and 35 days of treatment in the chondrogenic human bone marrow-derived
stem cells (hBMSC) transduced with respectively control vector (eGFP) and DIO2 (DIO2_eGFP; see online supplementary figure S3). (B–G) Sections
comparing control (top) and DIO2 overexpressing (bottom) chondrogenic hBMSC pellets at 21 and 35 days of treatment. (B, C) Alcian blue staining.
(D, E) Immunohistochemical staining of collagen type II. (F, G) Immunohistochemical staining of collagen type X. (B, D and F) Scale bar, 400 μm.
(C, E and G) Scale bar, 100 μm. The expression levels were arbitrarily defined as ‘1’ in the pellets grown under control conditions (white), and data
from the pellets overexpressing DIO2 (black) are given as mean±SEM. *p<0.05, **p<0.01, ***p<0.001. SEM<0.05 are not distinguishable in the
figure.
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homeostasis in contrast to DIO2 upregulation. Our data, there-
fore, indicate that upregulation of DIO2 does not affect the
‘early’ hypertrophic expression of COL10A1 but induces the
later ‘progression stage’ marker MMP13, and the ‘late stage’
markers ALPL and COL1A1.28 In our model, we used the
expression of EPAS1 and RUNX2 to show downstream effects
of upregulation of DIO2 and observed a significant positive
association between T3 and EPAS1. Although such an
observation based on association does not imply a direct causal
relationship, recent data of Chatonnet et al,29 showed, in a
ChIP-seq analysis in mouse C17.2 neural progenitor cells, that
EPAS1 harbours specific thyroid hormone nuclear receptor
(THR) binding sites and is directly reactive to thyroid hormone.
In view of these data, we advocate that active thyroid hormone,
likely by local DIO2 action, could have an important impact on
EPAS1 upregulation during the pathophysiology of OA.
Figure 4 Thyroid hormone is believed to be a key regulator in human cartilage development. (A–F) Sections of a representative donor (see online
supplementary figure S4) comparing control (top) and T3-treated (bottom) chondrogenic human bone marrow-derived stem cell (hBMSC) pellets at
7, 21 and 35 days of treatment. (A, B) Alcian blue staining. (C, D) Immunohistochemical staining of collagen type II. (E, F) Immunohistochemical
staining of collagen type X. (A, C and E) Scale bar, 400 μm. (B, D and F) Scale bar, 100 μm. (G) Mean surface area measurements at 7, 21 and
35 days of treatment with N=3 donors in each group. (H) Mean quantitative pixel-intensity measurements (see online supplementary figure S5) at 7,
21 and 35 days of treatment with N=5 donors in each group. (I) Log2 ratio of COL2A1 and COL1A1 with N=5 donors in each group. ( J) Mean
real-time qRT-PCR analysis of COL2A1, ACAN, COL10A1, COL1A1, ALPL, ADAMTS5 MMP13, RUNX2 and EPAS1 at 7, 21 and 35 days of treatment
in chondrogenic hBMSCs of N=5 donors in each group. The surface area measurement, pixel intensities and level of expression were arbitrarily
defined as ‘1’ in the pellets grown under control conditions (white) and the data from the pellets grown in the addition of excess T3 (black) are
given as mean±SEM. *p<0.05, **p<0.01, ***p<0.001. SEM<0.05 are not distinguishable in the figure.
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Additional studies are, however, necessary to elucidate whether
T3 is directly affecting expression of EPAS1, or RUNX2 for that
matter, by binding to a positional thyroid receptor in humans.
Despite the fact that the direction of gene expression changes
of COL2A1 and MMP13 upon addition of T3 to the culture
media appeared consistent with our overall results (figure 4J),
the mean differences in expression were not statistically signifi-
cant across the donors. Most likely this was the result of the
considerable heterogeneity in the differential gene expression
patterns of these specific genes across donors, especially with
respect to timing the respective downregulation and upregula-
tion at consecutive time points (see online supplementary figure
S4), a phenomenon generally recognised in the in vitro chon-
drogenesis models of primary hBMSCs.30
We detected several CpG dinucleotides across the DIO2 locus
that were differentially methylated between preserved and
Figure 5 Counteracting thyroid signalling by inhibiting deiodinases in human cartilage development. (A–F) Sections of a representative donor (see
online supplementary figure S4) comparing control (top) and IOP-treated (bottom) chondrogenic human bone marrow-derived stem cell (hBMSC)
pellets at 7, 21 and 35 days of treatment. (A, B) Alcian blue staining. (C, D) Immunohistochemical staining of collagen type II. (E, F)
Immunohistochemical staining of collagen type X. (A, C and E) Scale bar, 400 μm. (B, D and F) Scale bar, 100 μm. (G) Mean surface area
measurements at 7, 21 and 35 days of treatment with N=3 donors in each group. (H) Mean quantitative pixel-intensity measurements (see online
supplementary figure S5) at 7, 21 and 35 days of treatment with N=5 donors in each group. (I) Log2 ratio of COL2A1 and COL1A1 with N=5 donors
in each group. ( J) Mean real-time qRT-PCR analysis of COL2A1, ACAN, COL10A1, COL1A1, ALPL, ADAMTS5 MMP13, RUNX2 and EPAS1 at 7, 21
and 35 days of treatment in chondrogenic hBMSCs of N=5 donors in each group. The surface area measurement, pixel intensities and level of
expression were arbitrarily defined as ‘1’ in the pellets grown under control conditions (white) and the data from the pellets grown in the addition
of IOP (grey) are given as mean±SEM. *p<0.05, **p<0.01, ***p<0.001. SEM<0.05 are not distinguishable in the figure.
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OA-affected cartilage. Although we have only verified their
functionality with respect to DIO2 expression, we cannot
exclude that methylation at these sites regulates expression of
more distal genes. We found a consistent positive correlation
between methylation at CpG-2031 and DIO2 expression in
articular cartilage among carriers of the rs225014 risk allele,
which may not comply with the conventional inverse relation
between CpG methylation and gene expression. However, in
recent genome-wide approaches, it has been recognised that this
conventional relation primarily holds among CpG dinucleotides
residing in CpG islands and proximal promoters, whereas gene
body and distal enhancer methylation, as is the case for
CpG-2031, has been shown to correlate in either direction with
gene expression.31–33
With respect to our observations of DIO2 expression in pre-
served and osteoarthritic cartilage, it should be noted that, in
contrast to previously reported high upregulation of DIO2
expression in osteoarthritic compared with healthy cartilage,5 11
we showed a moderate upregulation in osteoarthritic compared
with preserved cartilage of the same joint only among carriers
of the rs225014 risk allele (figure 1I). This difference suggests
that upregulation of DIO2 expression may be an early event in
OA pathophysiology and might be set to continue progressively
among rs225014 risk allele carriers.
We were unable to validate the functionality of a putative CTCF
binding site directly at the rs225014 locus nor for that matter the
causality of the previously assessed consistent allelic imbalance.11
Possibly, the rs225014 SNP affects three-dimensional chromatin
conformations underlying the relation between the rs225014
tagged allelic imbalance and methylation-dependent upregulation
ofDIO2 among rs225014 riskallele carriers.
In conclusion, our data provide evidence in humans that
genetic predisposition combined with early OA-related changes
results in loss of epigenetic silencing of DIO2, which likely
induces EPAS1 and RUNX2 mediated upregulation of cartilage
matrix degrading enzymes (ADAMTS5 and MMP13) and min-
eralisation of matrix (ALPL and COL1A1), thereby driving the
OA process most distinctly among DIO2 risk allele carriers.
Furthermore, our data show that counteracting the thyroid sig-
nalling by inhibiting deiodinases could contribute to needed
novel therapeutic approaches of OA.
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